Found 541 articles
The company reported mid-stage and late-stage trial victories, one in small-cell lung cancer and another in colorectal cancer, as part of its second-quarter earnings on Thursday. No specific data was provided.
Mirati Therapeutics, Inc.® announced that the company granted equity awards to a new employee with a grant date of August 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employee's acceptance of employment with the company.
Incyte (Nasdaq:INCY) today reports 2023 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.
NovAccess Global Inc., a biomedical company developing novel immunotherapies for brain tumor patients, announced the signing of a Letter of Intent and formation of a partnership with BCN Biosciences to expand its immunotherapy platform.
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023.
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
Mirati Therapeutics, Inc. today announced the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for KRAZATI ®.
Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that Dan Paterson, President and Chief Operating Officer, has been promoted to President and Chief Executive Officer (CEO).
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology (Nasdaq: VSTM) (the “Company”) announced today that it has finalized with the U.S. Food and Drug Administration (FDA) the design of its confirmatory Phase 3 trial to evaluate the combination of avutometinib and defactinib for the treatment of recurrent low-grade serous ovarian cancer (LGSOC).
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
Acrivon Therapeutics, Inc. today announced that Charles (Chuck) Baum, M.D., Ph.D., founder, president, head of research and development, board member, and former chief executive officer of Mirati Therapeutics, has been appointed to Acrivon’s board of directors.
Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases
Mirati Therapeutics, Inc.® (NASDAQ: MRTX) announced today the Journal of Clinical Oncology published clinical results from the KRYSTAL-1 study of adagrasib, a potent and selective KRASG12C inhibitor, demonstrating durable IC activity in patients living with KRASG12C-mutated NSCLC with untreated CNS metastases.
An artificial intelligence computer program can read physicians' notes to accurately estimate patients' risk of death, length of hospital stay, and other factors important to care.
Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T. / 11:40 a.m. E.T.
Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced presentations and posters to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the utility of adagrasib across multiple tumor types.
The investigational kinase inhibitor failed to improve overall survival in the SAPPHIRE study of patients with non-squamous non-small cell lung cancer, causing Mirati to discontinue its development.
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced updated data from Part A of the ongoing registration-directed RAMP 201 trial evaluating the safety and efficacy of avutometinib alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer.
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
Mirati Therapeutics, Inc.®, a commercial-stage oncology company, announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis.
Verastem Oncology today announced the appointment of Karin Tollefson to its Board of Directors, effective May 15, 2023.
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
Aadi Bioscience, Inc. today announced financial results for the first quarter of 2023 and provided an initial update on the tumor-agnostic PRECISION 1 trial, a registration-directed Phase 2 study of nab-sirolimus in patients with solid tumors with pathogenic inactivating alterations in TSC1 or TSC2 genes.
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates.